Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

13 enrolled

Breast

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms

NCT04789096 2025-06-06

TUGETHER

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 3 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

HER2CLIMB-04

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

I-SPY

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

MK-7119-001

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

TrasTUCAN

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

TUGETHER

HER2CLIMB

MARGARET